Clinical study comparing the effectiveness and tolerance of 2 current and one new glibenclamide formulation
Lingg, G.; Haushofer, A.
Wiener Medizinische Wochenschrift 139(12): 281-284
1989
ISSN/ISBN: 0043-5341 PMID: 2506702 Document Number: 332445
In a clinical study efficacy and tolerance of Neogluconin (2.5 mg) a new galenical form of glibenclamide were compared with a conventional preparation (Euglucon 5). Neogluconin showed an improved absorption and comparable blood sugar levels at a dosage reduced by 25%. 25 outpatients suffering from Type II diabetes in a well balanced metabolic state and previously under Euglucon therapy for at least one year were changed to the new product. After 2 months of Neogluconin therapy blood sugar profiles, HbA1, C-peptide and cholesterin levels were unchanged in comparison to values determined during the previous Euglucon treatment. This confirms that Neogluconin produces a comparable favorable blood glucose lowering effect despite a 25% reduction in dosage.